The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Factors to consider when selecting myeloma patients for antibody therapy
In this video, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses patient selection for antibody therapy in relapsed/refractory multiple myeloma (R/R MM). Dr Popat explains that several factors must be considered when choosing between bispecific antibodies or antibody-drug conjugates (ADCs), such as the side effect profile of each agent, patient frailty, and the aggressiveness of disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
